Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PainReform ( (PRFX) ) has shared an announcement.
On March 16, 2026, Israel-based PRF Technologies entered a commercial collaboration agreement with Blade Ranger Ltd. to drive large-scale adoption of its DeepSolar AI analytics platform across utility-scale solar portfolios. Under the deal, Blade Ranger will introduce potential prospects for DeepSolar deployments of at least 150 megawatts each, with PRF retaining discretion over any resulting binding commercial contracts.
Blade Ranger may receive warrants to purchase up to 300,000 PRF ordinary shares at a nominal exercise price, contingent on successfully sourced prospects signing definitive agreements that meet minimum scope thresholds. The structure aligns Blade Ranger’s incentives with PRF’s push for revenue-generating enterprise deals, while Blade Ranger leverages its global network of solar developers, IPPs, investors, and asset owners to position DeepSolar as a performance-optimization tool in an increasingly digitalized and competitive solar market.
The collaboration is intended to expand DeepSolar’s reach among utility-scale operators seeking better forecasting, diagnostics, and operational insights to boost asset performance and revenue predictability. By formalizing this partnership, PRF aims to capitalize on rapid growth and rising complexity in the global solar sector, potentially enhancing its standing in AI-based energy optimization while maintaining strict control over which customer agreements qualify under the framework.
On March 17, 2026, PRF issued a press release highlighting that only executed, paying-customer contracts will count toward Blade Ranger’s warrant eligibility, and confirming mutual commitments around confidentiality and standard commercial terms. The company also noted that Blade Ranger must share in registration-related costs if PRF registers the resale of any warrant shares, underscoring a cost-conscious approach as PRF seeks to scale DeepSolar within an expanding renewable energy infrastructure market.
The most recent analyst rating on (PRFX) stock is a Sell with a $0.64 price target. To see the full list of analyst forecasts on PainReform stock, see the PRFX Stock Forecast page.
Spark’s Take on PRFX Stock
According to Spark, TipRanks’ AI Analyst, PRFX is a Neutral.
The score is weighed down primarily by weak financial performance (minimal revenue, widening losses, and rising cash burn alongside shrinking equity). Technicals also remain bearish with the stock trading below key moving averages, while valuation cannot be meaningfully assessed due to missing P/E and dividend yield data.
To see Spark’s full report on PRFX stock, click here.
More about PainReform
PRF Technologies Ltd., listed on Nasdaq as PRFX, operates a dual business model spanning pharmaceuticals and energy technology. In healthcare, it reformulates established therapeutics using a proprietary extended-release drug-delivery system aimed at prolonged post-surgical pain relief with reduced opioid reliance. In energy, its DeepSolar platform provides AI-driven digital asset-management and optimization software for utility-scale and solar-integrated environments, targeting both consumers and enterprises seeking improved energy forecasting, monitoring, and operational efficiency.
Average Trading Volume: 547,471
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.02M
For an in-depth examination of PRFX stock, go to TipRanks’ Overview page.